Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

IPO/Stock Watch

Market trends, bell-weather stocks, filings and IPOs...

Chi-Med Plans $500 Million IPO in Hong Kong, its Third Listing

Hansoh Pharma Re-Files for $500 Million to $1 Billion Hong Kong IPO

CanSino Biologics Climbs 58% Following $161 Million Hong Kong IPO

Tianjin's CanSino to Raise $160.5 Million for Novel Vaccines in Hong Kong IPO

CStone Pharma Completes $285 Million Hong Kong IPO; Trades Higher

Upcoming event
Shanghai , China
May 8-9, 2019
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China